Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of maintenance therapy

M Friedlander, J Rau, C K Lee, W Meier, A Lesoin, J-W Kim, A Poveda, M Buck, G Scambia, M Shimada, F Hilpert, M T King, P Debruyne, Alessandra Bologna, S Malander, B J Monk, E Petru, P Calvert, T J Herzog, C BarrettA du Bois

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of maintenance therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences